Connect with us

Hi, what are you looking for?

Jewish Business News


Israeli groundbreaking treatment inhibits cancer cell growth and changes these cells back to normal ones

Researchers at Ben-Gurion University develop a new molecule that inhibits the development of a protein that is most active in cancer cells.

A group of Israeli researchers have developed a groundbreaking molecule that inhibits cancer cell growth and changes these cells back to normal ones.

“Although this is in the early stages, we are excited with results that demonstrate this novel molecule’s potential for cancer treatment,” says Prof. Shoshan-Barmatz. “Basically, we’ve discovered a code for reprogramming cancer cells that causes them to lose their oncogenic features.”

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

The patented technology is based on preventing the expression of the mitochondrial gatekeeper protein VDAC1. Cancer cells have hundred times more VDAC1 than normal cells. It is highly expressed in different types of tumors and found to alter cancer hallmarks including the rewiring of pathways for growth and survival that underlie the malignant phenotype.

The team found that VDAC1 is the key to opening and closing the door to the mitochondria control cell metabolism. So they have developed the new molecule called siRNA, which silencing VDAC1, and when applied to the cells, they are able to inhibit cancer cell growth. Moreover, the cells were found to go back to normal ones.

“It reduced tumor growth and angiogenesis, reduced tumor invasiveness, and induced cancer stem cell disappearance and cell differentiation,” says Prof. Shoshan-Barmatz.

The study was conducted on brain cancer, lung cancer and breast cancer cells in both vitro and in mouse models.

But still, those normal cells have their original mutations, “we don’t fix the mutational genes. We do modify the activity of these genes to be like normal cells,” said prof. Shoshan-Barmatz.

This ability offers potentially wide applicability, since treating the cells in a culture with the siRNA resulted in significant inhibition of cancerous cell growth without affecting noncancerous cells ─ an indication of a potentially safe treatment, the University statement said.

Prof. Shoshan-Barmatz has previously demonstrated that silencing VDAC1 expression using the siRNA method ─ a tool that temporarily silences protein coding genes ─ leads to inhibition of cancer cell growth both in vitro and in mouse models of glioblastoma lung cancer and triple negative breast cancer.

Dr. Ora Horovitz, senior vice president of business development at BGN Technologies concluded: “We are now seeking partners to further develop and advance this promising treatment in a clinical setting in the hope that it will lead to a novel path for cancer treatment.”



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.